Cost regulators for NHS funded therapies in England and Wales have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
Read More
The National Institute for Health and Care Excellence has published draft guidance recommending GlaxoSmithKline’s gene therapy Strimvelis as an option for treating an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
Read More
UK regulators have awarded Orchard Therapeutics’ experimental ‘bubble baby’ disease therapy OTL-101 Promising Innovative Medicine status, pushing the drug closer to being accepted onto the Early Access to Medicines Scheme.
Read More
